Core B: Non-human Primate Core
核心B:非人类灵长类核心
基本信息
- 批准号:10731278
- 负责人:
- 金额:$ 45.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2028-03-31
- 项目状态:未结题
- 来源:
- 关键词:1 year oldAddressAdherenceAdjuvantAdolescentAdultAnimalsAntibodiesAuthorization documentationB cell differentiationB-LymphocytesBinding SitesBiological AssayBiological FactorsBiological ProductsBreedingCaliforniaCell LineageChildChildhoodClinicalClinical DataCollaborationsCommunicable DiseasesCommunicationDatabasesDecision MakingDedicationsDevelopmentElectronic MailEmulsionsEnsureEpidemicFoundationsGoalsHIVHIV envelope proteinHIV vaccineHIV/AIDSHealthHousingHumanIACUCImmuneImmune systemImmunityImmunizationImmunizeInfantInfectionInfrastructureKnowledgeLeadMacacaMacaca mulattaMaintenanceMissionModelingMolecularMonitorNatureObservational StudyParis, FrancePartner in relationshipPathway interactionsPregnancyPrimatesProceduresProductivityProgress ReportsRegimenRegulationResearchResearch Project GrantsResourcesRoleSamplingServicesSystems BiologyTimeTranslational ResearchUpdateVaccineeVaccinesauthorityexperienceexperimental studygenetic signaturegut microbiomehuman diseasehuman modelmeetingsmicrobiomeneutralizing antibodynonhuman primatepathogenprocedure safetyprogramssample collectionsymposiumvaccine deliveryvaccine strategy
项目摘要
ABSTRACT – Nonhuman Primate Core (Core B)
The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can achieve long-
term protective immunity, similar to that of vaccines that have nearly eliminated other global pathogens. The
induction of broadly neutralizing antibodies (bnAbs) against the HIV envelope (Env) is considered vital for an
effective HIV vaccine. Yet, despite the delineation of the coevolution of Env-specific antibodies and their cognate
Env intermediates from the germline BCR to bnAbs, few HIV vaccine strategies have been successful in eliciting
HIV Env Abs with broad heterologous neutralization capacity. Our knowledge about critical factors influencing B
cell differentiation and lineage commitment remains limited.
The proposed research is built on a foundation of prior research observations on the development of bnAbs in ~
50-60% of infant and adult rhesus macaques and humans immunized with germline-targeting (gt) BG505 GT1.1
SOSIP with adjuvant, and the opportunities provided by the infant RM model to define the specific biological
factors that determine B cell lineage commitment by comparing vaccinees with or without bnAb development.
Systems biology approaches can be useful to define early immune and molecular gene signatures after the
vaccine prime immunization and the role of the intestinal microbiome in vaccine-induced bnAb development.
Applying systems biology approaches, the objective of the overall studies is to determine how the modulation
of the vaccine prime by different adjuvants and vaccine delivery platforms (Project 1) and changes in the infant
microbiome (Project 2) alter the developmental pathways that lead to the induction of bnAbs. We hypothesize
that the dynamic nature of the infant immune system and microbiome can be exploited to optimize the induction
of bnAbs by HIV vaccines. These questions will be addressed via studies in the infant macaque model.
The Nonhuman Primate (NHP) Core is an integral component of the overall HIVRAD Program and
provides direct support to the Projects by coordinating and implementing all the NHP experiments
(including regulatory approvals, and all procedures related to immunizations and sample collections). This
Core has a longstanding track-record of collaboration with the 2 Project Leads/Overall P.I’s, and will
communicate frequently with both Projects and other Cores to assure all the experimental needs are met with
due diligence. The NHP Core uses the unique resources and infrastructure of the California National Primate
Research Center (CNPRC), out of which it operates, and the expertise of the Core Lead and staff. The CNPRC
is built on a service-oriented and interdisciplinary mission of advancing non-human primate models of human
diseases and translational research. Resources at CNPRC include a large rhesus macaque breeding colony,
experience with time-mated pregnancies and rearing of infant macaques, and all other procedures of
monitoring and sample collections that are essential to the successful completion of the Projects.
抽象-非人灵长类核心(核心B)
只有当一种有效的疫苗方案能够实现长效...
长期保护性免疫,类似于几乎消除了其他全球病原体的疫苗。这个
诱导针对HIV包膜(Env)的广谱中和抗体(BNAbs)被认为对
有效的艾滋病毒疫苗。然而,尽管环境特异性抗体及其同源物的共同进化被描绘出来
从生殖系bcr到bNAbs的env中间体,很少有HIV疫苗策略能成功地诱导出
具有广泛的异源中和能力的HIV包膜抗体。我们对影响B的关键因素的认识
细胞分化和谱系承诺仍然有限。
建议的研究是建立在先前研究观察到的bNAbs在~
50%-60%的婴儿和成年恒河猴和人类接种了生殖系靶向(GT)BG505 GT1.1
辅助剂,以及婴儿RM模型提供的机会,以定义特定的生物学
通过比较有或没有发育bNab的受试者来决定B细胞谱系承诺的因素。
系统生物学方法可用于定义早期免疫和分子基因特征。
疫苗初始免疫和肠道微生物群在疫苗诱导的bNab发育中的作用。
应用系统生物学的方法,整体研究的目标是确定如何调节
不同佐剂和疫苗投放平台的初级疫苗(项目1)和婴儿的变化
微生物组(项目2)改变导致bNAbs诱导的发育途径。我们假设
可以利用婴儿免疫系统和微生物组的动态性质来优化诱导
HIV疫苗对bNAbs的影响。这些问题将通过对婴儿猕猴模型的研究来解决。
非人灵长类(NHP)核心是整个HIVRAD计划的组成部分,
通过协调和实施所有NHP实验,为项目提供直接支持
(包括监管批准,以及与免疫接种和样本采集有关的所有程序)。这
CORE拥有与2个项目负责人/整体P.I合作的长期记录,并将
经常与项目和其他核心进行沟通,以确保满足所有实验需求
尽职调查。NHP核心使用加州国家灵长类动物独特的资源和基础设施
研究中心(中国石油天然气集团公司),以及核心领导和工作人员的专业知识。中国人民大会党
是建立在面向服务和跨学科的使命之上的,即推动人类的非人类灵长类模型
疾病和翻译研究。CNPRC的资源包括一个大型恒河猴繁殖群体,
有时间配对怀孕和哺育猕猴幼崽的经验,以及所有其他程序
监测和样品采集对项目的成功完成至关重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kristina De Paris其他文献
Kristina De Paris的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kristina De Paris', 18)}}的其他基金
Project 1: The impact of innate immune responses on the development of broadly neutralizing antibodies by vaccination
项目 1:先天免疫反应对通过疫苗接种产生广泛中和抗体的影响
- 批准号:
10731281 - 财政年份:2023
- 资助金额:
$ 45.83万 - 项目类别:
Project 2: Microbial determinants of HIV broadly-neutralizing antibody precursor induction in infants
项目2:婴儿中HIV广泛中和抗体前体诱导的微生物决定因素
- 批准号:
10731282 - 财政年份:2023
- 资助金额:
$ 45.83万 - 项目类别:
Determinants of HIV broadly-neutralizing antibody precursor induction in infants
婴儿中 HIV 广泛中和抗体前体诱导的决定因素
- 批准号:
10731276 - 财政年份:2023
- 资助金额:
$ 45.83万 - 项目类别:
Vaccine-induced SARS-CoV-2-specific T cell responses in patients with X-linked Agammaglobulinemia
X 连锁无丙种球蛋白血症患者中疫苗诱导的 SARS-CoV-2 特异性 T 细胞反应
- 批准号:
10593523 - 财政年份:2023
- 资助金额:
$ 45.83万 - 项目类别:
Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques
SARS-CoV-2 稳定预灌注 Spike 蛋白疫苗在幼年恒河猴中的免疫原性和功效
- 批准号:
10223634 - 财政年份:2020
- 资助金额:
$ 45.83万 - 项目类别:
Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in Infants
舌下注射疫苗预防婴儿经口艾滋病毒传播
- 批准号:
10172886 - 财政年份:2018
- 资助金额:
$ 45.83万 - 项目类别:
Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in Infants
舌下注射疫苗预防婴儿经口艾滋病毒传播
- 批准号:
10425465 - 财政年份:2018
- 资助金额:
$ 45.83万 - 项目类别:
The Pros and Cons of Trained Immunity Induced by Vaccines for Tuberculosis Prevention
结核病预防疫苗诱导的训练免疫的利与弊
- 批准号:
9207318 - 财政年份:2016
- 资助金额:
$ 45.83万 - 项目类别:
相似海外基金
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 45.83万 - 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
- 批准号:
10738120 - 财政年份:2023
- 资助金额:
$ 45.83万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10526768 - 财政年份:2022
- 资助金额:
$ 45.83万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10701072 - 财政年份:2022
- 资助金额:
$ 45.83万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10679092 - 财政年份:2021
- 资助金额:
$ 45.83万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10432133 - 财政年份:2021
- 资助金额:
$ 45.83万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10327065 - 财政年份:2021
- 资助金额:
$ 45.83万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10377366 - 财政年份:2019
- 资助金额:
$ 45.83万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10574496 - 财政年份:2019
- 资助金额:
$ 45.83万 - 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
- 批准号:
9403567 - 财政年份:2017
- 资助金额:
$ 45.83万 - 项目类别: